AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
AAPL   320.66 (+0.56%)
MSFT   184.75 (+0.68%)
FB   238.76 (+1.63%)
GOOGL   1,439.42 (+1.85%)
AMZN   2,447.72 (+0.44%)
NVDA   356.63 (-1.22%)
CGC   20.40 (+5.05%)
BABA   206.30 (+3.30%)
MU   45.96 (+2.27%)
AMD   55.21 (+0.07%)
T   30.90 (+3.41%)
ACB   15.90 (-0.69%)
F   5.99 (+6.02%)
GILD   72.92 (-0.57%)
NFLX   417.81 (-2.68%)
BAC   23.78 (+4.90%)
BA   144.20 (+4.85%)
Log in

LON:AMYTAmryt Pharma Share Price, Forecast & News

GBX 115
+2.50 (+2.22 %)
(As of 05/26/2020 08:42 AM ET)
Add
Compare
Today's Range
112
Now: GBX 115
115
50-Day Range
100
MA: GBX 106.74
112.50
52-Week Range
12.38
Now: GBX 115
143
Volume6,233 shs
Average Volume184,629 shs
Market Capitalization£177.67 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Amryt Pharma plc, a commercial stage pharmaceutical company, focuses on the acquisition, development, and commercialization of medicines for the treatment of rare and orphan diseases. The company operates through two segments, Commercial and Research and Development. It offers Lojuxta (lomitapide), a drug used to treat a rare life-threatening disease Homozygous Familial Hypercholesterolaemia; and a range of dermo cosmetic products under the Imlan brand. Its products in development includes AP101 (Oleogel-S10), a prescription medicine used for the treatment of partial-thickness wounds in adults, which is in Phase III clinical trial; and AP102, a somatostatin analogue peptide medicine, which is in pre-clinical stage for patients with rare neuoendocrine diseases, such as acromegaly; and AP103, a gene therapy product line. The company operates in European Economic Area, the Middle East, North Africa, Turkey, Israel, and Switzerland. Amryt Pharma plc is based in London, the United Kingdom.
Read More
Amryt Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 0.0Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

0.63 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
CUSIPN/A
CIKN/A
Phone+44-20-34155730

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book ValueGBX 4.60 per share

Profitability

Miscellaneous

Employees41
Market Cap£177.67 million
Next Earnings DateN/A
OptionableNot Optionable

Receive AMYT News and Ratings via Email

Sign-up to receive the latest news and ratings for AMYT and its competitors with MarketBeat's FREE daily newsletter.

Amryt Pharma (LON:AMYT) Frequently Asked Questions

How has Amryt Pharma's stock been impacted by COVID-19 (Coronavirus)?

Amryt Pharma's stock was trading at GBX 104 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, AMYT stock has increased by 10.6% and is now trading at GBX 115. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Amryt Pharma?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amryt Pharma in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Amryt Pharma.

Has Amryt Pharma been receiving favorable news coverage?

Press coverage about AMYT stock has trended negative recently, according to InfoTrie. The research firm scores the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amryt Pharma earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the stock's share price in the near future. View the latest news aboutAmryt Pharma.

Who are some of Amryt Pharma's key competitors?

What other stocks do shareholders of Amryt Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amryt Pharma investors own include Chubb (CB), The Parkmead Group (PMG), Himax Technologies (HIMX), Atalaya Mining (ATYM), BK IRELAND GRP/ADR (BKRIY), Concepta (CPT), Faroe Petroleum (FPM), Vectura Group (VEC), Xcite Energy (XEL) and BowLeven (BLVN).

Who are Amryt Pharma's key executives?

Amryt Pharma's management team includes the following people:
  • Dr. Joseph Wiley, Founder, CEO & Exec. Director (Age 48)
  • Mr. Rory Nealon, CFO, COO, Company Sec. & Exec. Director (Age 51)
  • Dr. Tobias Zahn, Head of Clinical Operations
  • Dr. Mark Sumeray, Chief Medical Officer (Age 53)
  • Mr. David Allmond, Chief Commercial Officer

What is Amryt Pharma's stock symbol?

Amryt Pharma trades on the London Stock Exchange (LON) under the ticker symbol "AMYT."

How do I buy shares of Amryt Pharma?

Shares of AMYT and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.

What is Amryt Pharma's stock price today?

One share of AMYT stock can currently be purchased for approximately GBX 115.

How big of a company is Amryt Pharma?

Amryt Pharma has a market capitalization of £177.67 million. Amryt Pharma employs 41 workers across the globe.

What is Amryt Pharma's official website?

The official website for Amryt Pharma is www.amrytpharma.com.

How can I contact Amryt Pharma?

Amryt Pharma's mailing address is Ivybridge House, 1 Adam Street, LONDON, WC2N 6LE, United Kingdom. The company can be reached via phone at +44-20-34155730.

This page was last updated on 5/26/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.